Belgrade, Mont.-based Xtant Medical reported its expected third quarter 2016 revenue, according to EIN News.
Here are four highlights:
1. Xtant anticipates its third quarter revenue to be between $23 million and $23.3 million.
2. This expected revenue represents a 10 percent to 11.5 percent increase compared to pro forma third quarter of 2015 revenue.
3. Additionally, the anticipated revenue reflects a sequential increase of 7.2 percent to 8.6 percent compared to second quarter 2016 revenue.
4. Xtant Medical manufactures regenerative medicine products.